Terms: = Germ cell tumor AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
17 results:
1. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large cell Neuroendocrine Carcinomas with Distinct Prognosis.
Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
[TBL] [Abstract] [Full Text] [Related]
2. Amentoflavone Effectively Blocked the tumor Progression of Glioblastoma via Suppression of erk/NF-
Hsu FT; Chiang IT; Kuo YC; Hsia TC; Lin CC; Liu YC; Chung JG
Am J Chin Med; 2019; 47(4):913-931. PubMed ID: 31096773
[TBL] [Abstract] [Full Text] [Related]
3. HPCAL1 promotes glioblastoma proliferation via activation of Wnt/β-catenin signalling pathway.
Zhang D; Liu X; Xu X; Xu J; Yi Z; Shan B; Liu B
J Cell Mol Med; 2019 May; 23(5):3108-3117. PubMed ID: 30843345
[TBL] [Abstract] [Full Text] [Related]
4. Distinct Molecular Profiles and Immunotherapy Treatment outcomes of V600E and V600K
Pires da Silva I; Wang KYX; Wilmott JS; Holst J; Carlino MS; Park JJ; Quek C; Wongchenko M; Yan Y; Mann G; Johnson DB; McQuade JL; Rai R; Kefford RF; Rizos H; Scolyer RA; Yang JYH; Long GV; Menzies AM
Clin Cancer Res; 2019 Feb; 25(4):1272-1279. PubMed ID: 30630828
[TBL] [Abstract] [Full Text] [Related]
5. The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis.
Salama Y; Lin SY; Dhahri D; Hattori K; Heissig B
FASEB J; 2019 Mar; 33(3):3465-3480. PubMed ID: 30458112
[TBL] [Abstract] [Full Text] [Related]
6. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.
Deng MY; Sill M; Chiang J; Schittenhelm J; Ebinger M; Schuhmann MU; Monoranu CM; Milde T; Wittmann A; Hartmann C; Sommer C; Paulus W; Gärtner J; Brück W; Rüdiger T; Leipold A; Jaunmuktane Z; Brandner S; Giangaspero F; Nozza P; Mora J; Morales la Madrid A; Cruz Martinez O; Hansford JR; Pietsch T; Tietze A; Hernáiz-Driever P; Stoler I; Capper D; Korshunov A; Ellison DW; von Deimling A; Pfister SM; Sahm F; Jones DTW
Acta Neuropathol; 2018 Aug; 136(2):239-253. PubMed ID: 29766299
[TBL] [Abstract] [Full Text] [Related]
7. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract] [Full Text] [Related]
8. ATF4 Targets RET for Degradation and Is a Candidate tumor Suppressor Gene in Medullary Thyroid Cancer.
Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
[TBL] [Abstract] [Full Text] [Related]
9. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
Circelli L; Sciammarella C; Guadagno E; Tafuto S; del Basso de Caro M; Botti G; Pezzullo L; Aria M; Ramundo V; Tatangelo F; Losito NS; Ieranò C; D'Alterio C; Izzo F; Ciliberto G; Colao A; Faggiano A; Scala S
Oncotarget; 2016 Apr; 7(14):18865-75. PubMed ID: 26934559
[TBL] [Abstract] [Full Text] [Related]
10. Overexpression of TIP30 inhibits the growth and invasion of glioma cells.
Hu Y; Chen F; Liu F; Liu X; Huang N; Cai X; Sun Y; Li A; Luo R
Mol Med Rep; 2016 Jan; 13(1):605-12. PubMed ID: 26718891
[TBL] [Abstract] [Full Text] [Related]
11. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
[TBL] [Abstract] [Full Text] [Related]
12. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
[TBL] [Abstract] [Full Text] [Related]
13. Pro-survival AKT and erk signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.
Golding SE; Morgan RN; Adams BR; Hawkins AJ; Povirk LF; Valerie K
Cancer Biol Ther; 2009 Apr; 8(8):730-8. PubMed ID: 19252415
[TBL] [Abstract] [Full Text] [Related]
14. Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma.
Jørgensen K; Davidson B; Flørenes VA
Mod Pathol; 2006 Nov; 19(11):1446-55. PubMed ID: 16951673
[TBL] [Abstract] [Full Text] [Related]
15. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, erk, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract] [Full Text] [Related]
16. Overexpression of collagenase 1 (MMP-1) is mediated by the erk pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.
Huntington JT; Shields JM; Der CJ; Wyatt CA; Benbow U; Slingluff CL; Brinckerhoff CE
J Biol Chem; 2004 Aug; 279(32):33168-76. PubMed ID: 15184373
[TBL] [Abstract] [Full Text] [Related]
17. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/erkM.
Calabrese C; Frank A; Maclean K; Gilbertson R
J Biol Chem; 2003 Jul; 278(27):24951-9. PubMed ID: 12709419
[TBL] [Abstract] [Full Text] [Related]
